WO2002002142B1 - Papillomavirus vaccine - Google Patents

Papillomavirus vaccine

Info

Publication number
WO2002002142B1
WO2002002142B1 PCT/SE2001/001501 SE0101501W WO0202142B1 WO 2002002142 B1 WO2002002142 B1 WO 2002002142B1 SE 0101501 W SE0101501 W SE 0101501W WO 0202142 B1 WO0202142 B1 WO 0202142B1
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
vaccine according
sequence
nucleic acid
vaccine
Prior art date
Application number
PCT/SE2001/001501
Other languages
French (fr)
Other versions
WO2002002142A1 (en
Inventor
Stefan Schwartz
Original Assignee
Stefan Schwartz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stefan Schwartz filed Critical Stefan Schwartz
Priority to AU2001266534A priority Critical patent/AU2001266534A1/en
Publication of WO2002002142A1 publication Critical patent/WO2002002142A1/en
Publication of WO2002002142B1 publication Critical patent/WO2002002142B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention within the field of papillomavirus vaccines and is related to nucleic acid vaccines comprising nucleic acid sequences encoding papillomavirus proteins, such as L1 and L2. More closely, the invention relates to a human papilloma virus (HPV) vaccine comprising a HPV nucleic acid which encodes HPV protein which is effectively expressed in human cells and which leads to an effective immune response. This is achieved by inactivating the negative regulatory elements of the HPV nucleic acid.

Claims

18AMENDED CLAIMS[received by the International Bureau on 03 January 2002 (03.01.02); original claim 1 cancelled; original claims 2-15 renumbered as claims 1-14 (2 pages)]
1. A human papilloma virus (HPV) vaccine comprising a HPV nucleic acid in which negative regulatory element(s) have been inactivated, deleted or substituted with HPV protein encoding sequences lacking said element(s).
2. A vaccine according to claim 1 , comprising a synthetic HPV nucleic acid in which negative regulatory element(s) have been inactivated by genetically altering said nucleic acid without changing the coding sequence of its corresponding protein.
3. A vaccine according to claims 1 or 2, wherein the nucleic acid is DNA or RNA.
4. A vaccine according to claim 3, comprising:
- a nucleic acid vector;
- a synthetic HPV DNA sequence; and
- elements necessary for expressing said sequence when the vaccine has been introduced into a human subject.
5. A vaccine according to claim 3, wherein the HPV nucleic acid is in vitro synthesised, capped and polyadenylated RNA.
6. A vaccine according to claim 5, wherein the RNA is self-replicating.
7. A vaccine according to one or more of the above claims, wherein the synthetic HPV sequence is/are derived from oncogenic HPV.
8. A vaccine according to claim 7, wherein the synthetic HPV sequence is/ are derived from HPV late sequence(s).
9. A vaccine according to claim 8, wherein the HPV late sequence is HPV 16 LI .
10. A vaccine according to claim 9, wherein the first 25% of the nucleic acids in the sequence have been replaced with other nucleic acids in a way not changing the amino acid sequence of the gene product.
1 1. A vaccine according to one or more of the above claims, comprising a combination of HPV sequences derived from one or more HPV types.
12. A vaccine according to claim 1 1, wherein the sequences are derived from HPV 6, 11, 16, 18, 31, 33 and/or 45.
13. A vaccine according to claim 1 1, further comprising HPV early sequences.
14. A vaccine according to claim 11, 12 or 13, comprising immune response enhancer(s) .
PCT/SE2001/001501 2000-07-03 2001-06-29 Papillomavirus vaccine WO2002002142A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001266534A AU2001266534A1 (en) 2000-07-03 2001-06-29 Papillomavirus vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002498-4 2000-07-03
SE0002498A SE0002498D0 (en) 2000-07-03 2000-07-03 Papillomavirus vaccine

Publications (2)

Publication Number Publication Date
WO2002002142A1 WO2002002142A1 (en) 2002-01-10
WO2002002142B1 true WO2002002142B1 (en) 2002-03-21

Family

ID=20280346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/001501 WO2002002142A1 (en) 2000-07-03 2001-06-29 Papillomavirus vaccine

Country Status (3)

Country Link
AU (1) AU2001266534A1 (en)
SE (1) SE0002498D0 (en)
WO (1) WO2002002142A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719981B1 (en) 1998-11-27 2004-04-13 Akzo Nobel N.V. Stable, attenuated rabies virus mutants and live vaccines thereof
DE102008010954A1 (en) * 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA vaccine for the therapy and prophylaxis of cervical cancer and its premalignant precursors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus

Also Published As

Publication number Publication date
SE0002498D0 (en) 2000-07-03
AU2001266534A1 (en) 2002-01-14
WO2002002142A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
CA2202090A1 (en) Papilloma virus-like particles, fusion proteins as well as processes for their production
WO2000073316A3 (en) Virus immunologic determinants
JP2002510494A5 (en)
JP2007516696A5 (en)
WO2001027304A3 (en) Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
WO2000053767A3 (en) Nucleic acid respiratory syncytial virus vaccines
EP0910406A4 (en) Recombinant canine herpesviruses
MXPA02006888A (en) Recombinant flaviviruses and methods of use thereof.
RU2006105498A (en) POLYEPEPTIDES FOR THE INDUCTION OF A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
WO2001038357A3 (en) Jaffa, a novel fibroblast growth factor family member and uses therefor
AU3406595A (en) Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2002096939A3 (en) Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
EP1613345A4 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
ATE408620T1 (en) NON-IMMUNOSUPRESSIVE IMMUNOGENIC OR VACCINE COMPOSITION CONTAINING A MUTATED E7 PROTEIN FROM THE HUMAN PAPILLOMA VIRUS HPV-16
WO2003097673B1 (en) Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide,virus-like particles prepared therefrom and a method for preparing the particles.
WO2002002142B1 (en) Papillomavirus vaccine
MXPA02012593A (en) Bvdv virus-like particles.
EP1829552A3 (en) Chlamydia PMP proteins, gene sequences and uses thereof
EP1427443A4 (en) Vaccine using papilloma virus e proteins delivered by viral vector
WO2000066743A3 (en) Viral expression vectors
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
WO2002038769A3 (en) Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP